Table 3

Propensity Analysis of the Risk of Certain Adverse Events of Interest in Alirocumab-Treated Patients With 2 or More Consecutive Low-Density Lipoprotein Cholesterol Values <25 mg/dl (Safety Population; Pool of Phase 3 Studies)

LDL-C ≥25 mg/dl (n = 2,371)LDL-C <25 mg/dl (n = 811)HR (95% CI) for LDL-C <25 vs. ≥25 mg/dl
Neurological events4.4 (104)2.5 (20)0.53 (0.30–0.93)
Neurocognitive disorders1.1 (25)0.6 (5)0.38 (0.13–1.09)
Musculoskeletal events17.0 (403)14.2 (115)0.75 (0.59–0.97)
Diabetes mellitus or diabetic complications event (regardless of baseline status)4.0 (94)6.0 (49)1.09 (0.72–1.65)
Diabetes mellitus or diabetic complication event (patients with diabetes at baseline)9.2 (62)12.0 (37)1.05 (0.66–1.68)
Ophthalmologic events2.0 (47)1.6 (13)0.64 (0.31–1.31)
Cataracts0.8 (19)2.6 (21)3.4 (1.58–7.35)
Hepatic disorders3.0 (72)2.0 (16)1.01 (0.54–1.88)

Values are % (n).

CI = confidence interval; HR = hazard ratio; LDL-C = low-density lipoprotein cholesterol.

  • p = 0.0018. All other comparisons were not significant. For definitions of these categories, see Table 2.